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Abstract
Background: Human duodenal mucosa secretes increased levels of satiety signals upon exposure to intact protein.
However, after oral protein ingestion, gastric digestion leaves little intact proteins to enter the duodenum. This study
investigated whether bypassing the stomach, through intraduodenal administration, affects hormone release and food-
intake to a larger extent than orally administered protein in both lean and obese subjects.
Methods: Ten lean (BMI:23.060.7 kg/m
2) and ten obese (BMI:33.461.4 kg/m
2) healthy male subjects were included. All
subjects randomly received either pea protein solutions (250 mg/kg bodyweight in 0.4 ml/kg bodyweight of water) or
placebo (0.4 ml/kg bodyweight of water), either orally or intraduodenally via a naso-duodenal tube. Appetite-profile,
plasma GLP-1, CCK, and PYY concentrations were determined over a 2 h period. After 2 h, subjects received an ad-libitum
meal and food-intake was recorded.
Results: CCK levels were increased at 10(p,0.02) and 20(p,0.01) minutes after intraduodenal protein administration (IPA),
in obese subjects, compared to lean subjects, but also compared to oral protein administration (OPA)(p,0.04). GLP-1 levels
increased after IPA in obese subjects after 90(p,0.02) to 120(p,0.01) minutes, compared to OPA. Food-intake was reduced
after IPA both in lean and obese subjects (-168.9640 kcal (p,0.01) and 2298.2644 kcal (p,0.01), respectively), compared
to placebo. Also, in obese subjects, food-intake was decreased after IPA (2132.6642 kcal; p,0.01), compared to OPA.
Conclusions: Prevention of gastric proteolysis through bypassing the stomach effectively reduces food intake, and seems to
affect obese subjects to a greater extent than lean subjects. Enteric coating of intact protein supplements may provide an
effective dietary strategy in the prevention/treatment of obesity.
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Introduction
Food ingestion triggers a number of stimuli, such as the release
of the gastrointestinal hormones cholecystokinin (CCK), glucagon-
like peptide 1 (GLP-1) and peptide YY (PYY). These hormones are
known to be involved in the modulation of appetite sensations.
CCK is produced by I-cells in the duodenal and jejunal mucosa,
and is secreted in response to luminal food compounds, especially
lipids and proteins [1]. GLP-1 and PYY are produced primarily by
the L-cells in the more distal small intestine and colon. Ingested
nutrients stimulate CCK-, GLP-1-, and PYY secretion indirectly
by neurohumoral mechanisms, e.g. feedback mechanisms of
hormones from a more distal part of the small intestine, as well
as by direct sensing mechanisms at the intestinal mucosa [2,3].
Previously, it was demonstrated that the plasma levels of GLP-1
were elevated in obese rats, compared to lean rats [4]. Others found
that levels of ghrelin and obestatin were decreased in obese children,
compared to lean children [5]. Also, PYY levels are lower in obese
subjectscompared tolean subjects[6].Thesedataindicatethatthere
are significant differences between lean and obese subjects with
respecttohormonerelease,andthatthegutmayresponddifferentto
ingested nutrients in obese subjects, compared to lean subjects.
Among all properties of food, the total energy content and the
macronutrient composition appears to be one of the major
determinants of the control of food intake. Recent literature points
to the effect of dietary protein in reducing food intake by improving
satiety sensations [7,8]. It seems that proteins have the highest
satiating effect when compared to carbohydrates and in particular
fats in humans and rats [9,10], although the nature of the protein
can influence its satiating effects. In most cases, high-protein meals
increase feelings of satiety and decrease subsequent energy intake
compared with high-carbohydrate or high-fat meals [11].
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24878From previous work it is well known that proteins have the
ability to affect food intake and appetite in several species,
including humans [7,12,13,14]. A variety of physiological mecha-
nisms activated by protein ingestion may act in concert to exert
their satiating effect. One of the physiological processes through
which proteins appear to induce satiety is by stimulating satiety
hormone secretion [15]. However, little is known about the
satiating properties of proteins originating from different sources.
In previous studies we showed that proteins and especially
codfish, egg, pea, and wheat exert strong effects on satiety
hormone release in an in vitro setting. Remarkably, the hydroly-
sates showed weaker effects with respect to hormone release, than
the intact protein [16]. We also demonstrated that these intact
proteins exert different effects on satiety hormone release in
human duodenal tissue. Exposing intestinal tissue to intact pea and
wheat protein induced an increase in the release of both CCK and
GLP-1, whereas al the other tested proteins did not affect the
hormone release [17].
It was shown previously in rats that intraduodenal infusion of
dietary protein resulted inincreased plasma levelsof CCK compared
to intragastric infusion [18]. We hypothesize that 1) intraduodenal
infusion of intact dietary proteins in humans will induce stronger
effects on satiety hormone release and satiation, when compared to
orally ingested dietary proteins, and that 2) there are differences in
hormone secretion between lean and obese subjects. To investigate
this, the effects of different administration routes of pea protein on
plasma satiety hormone levels, feelings of hunger and satiety, and
food intake were investigated in both lean and obese subjects.
Results
Satiety and well-being scores
All fasting scores did not differ between treatments for both lean
and obese subjects. There was also no difference between placebo
treatments in both groups. For lean subjects, feelings of hunger
increased over time (figure 1A), but there were no significant
differences between treatments. Obese subjects reported decreased
feeling of hunger after 30 minutes with the oral protein treatment
(figure 1B), compared to the other treatments. After 120 minutes,
no differences were observed in feelings of hunger between
treatments in obese subjects. Also, obese subjects reported to feel
less hungry at 120 minutes after intraduodenal protein treatment
when compared to lean subjects with the same treatment.
Even though we did not see differences in feeling of hunger
in lean subjects, these subjects felt more full after the intraduodenal
treatment (figure 1C), compared to the placebo treatment. There
were no differences in the oral treatment. Between 60 and 90
minutes, obese subjects felt more full after intraduodenal protein
treatment (figure 1D), compared to placebo treatment. However,
there were no differences between the lean and obese group.
Satiety feelings did not change over time for lean subjects
(figure 1E), whereas for obese subjects, satiety feelings were
significantly increased at 120 minutes after oral protein ingestion,
compared to oral placebo ingestion (figure 1F).
There were no differences in feelings of thirst, desire to eat, or
feelings of well-being between the treatments and between the
groups. Subjects scored no feelings of nausea, intestinal cramps,
diarrhea, headache, or dizziness during any treatment.
Plasma Ghrelin
Baseline levels of total Ghrelin did not differ between study
days, and between groups (data not shown). Placebo treatments or
protein treatments did not affect the total Ghrelin levels in both
groups (data not shown).
Plasma CCK
Baseline plasma CCK concentrations did not differ between
study days, and between groups (data not shown). Placebo
treatments did not affect the plasma CCK levels in all treatments
in both groups. Oral ingestion of pea protein in lean subjects
(figure 2A) resulted in significantly increased levels of CCK for
the first 10 minutes, whereas after intraduodenal infusion of pea,
CCK levels where significantly increased during the first 15
minutes. After 30 minutes, CCK levels returned to baseline for
both protein treatments. More pronounced differences were
observed in obese subjects (figure 2B). After oral protein ingestion,
CCK levels were significantly increased for the first 10 minutes,
when compared to the placebo treatment. However, after intra-
duodenal administration of pea protein, CCK levels were
significantly increased during the first 15 minutes, when compared
to the placebo treatment, but also when compared to the oral
treatments. Intraduodenal protein treatment showed stronger
effects on CCK release in obese subjects than in lean subjects.
Plasma active GLP-1
Baseline plasma GLP-1 concentrations did not differ between
study days, and between groups (data not shown). Placebo
treatments did not affect the plasma GLP-1 levels in all treatments
in both groups. Both protein treatments showed no effect on GLP-
1 release in lean subjects (figure 3A), with the exception of the
oral protein treatment at time point 15 minutes. Here GLP-1
levels were significantly increased when compared to the placebo
treatment. In obese subjects, the oral protein treatment did not
affect GLP-1 release when compared to the placebo treatment
(figure 3B). Intraduodenal protein administration in obese subjects
resulted in significantly increased levels after 90 minutes until the
end of the test, compared to the placebo treatment, but also
compared to the oral treatment.
Plasma PYY
Baseline plasma PYY concentrations did not differ between
study days, and between groups (data not shown). Placebo
treatments did not affect the plasma PYY levels in all treatments
in both groups. In lean subjects, intraduodenal protein adminis-
tration induced stronger effects on PYY release compared to oral
protein ingestion (figure 4A). PYY levels were increased after 15
minutes, until the end of the test, whereas during the oral
treatment, PYY levels were only increased after 60 minutes,
compared to the placebo. The effects of protein administration in
obese subjects did not differ between oral and intraduodenal
treatment (figure 4B). For both treatments, PYY levels were
significantly increased after 30 minutes, until the end of the test,
compared to the placebo treatment.
Food intake
Consumption of the ad libitum meal did not differ between lean
and obese subjects. Orally ingested protein did not affect the
consumption of the meal, whereas intraduodenally administered
protein decreased food intake in both lean and obese subjects
(-168.9 6 40 kcal (p,0.01) and 2298.2 6 44 kcal (p,0.01),
respectively). Obese subjects also consumed significantly less after
the intraduodenal protein treatment when compared to the oral
protein treatment (2132.6 6 42 kcal; p,0.01)( figure 5).
Discussion
This study demonstrated for the first time that in both lean and
obese humans, intraduodenal administration of intact pea protein
is effective in reducing food intake, whereas no differences between
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PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e24878Figure 1. Changes in hunger, fullness, and satiety (mmVAS) after oral and intraduodenal treatments with pea protein and placebo.
Feelings of hunger did not change in lean subjects after between treatments (A), whereas in obese subjects, hunger decreased at 30 minutes after
the oral pea protein ingestion (B). Feelings of fullness were increased after intraduodenal pea protein treatment for both lean (C) and obese (D)
subjects. Satiety did not change over time when compared to placebo treatments for both lean (E) and obese (F) subjects. Values are expressed as
mean 6 SEM. * Significantly different from placebo treatment (p,0.05). # Significantly different from oral protein treatment (p,0.05).
doi:10.1371/journal.pone.0024878.g001
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the protein. This effect was not seen when the protein was given
orally to the same subjects. Also, intraduodenal infusion of protein
resulted in stronger effects on CCK release in obese subjects than
in lean subjects, whereas effects on GLP-1 and PYY release were
comparable in both groups.
Digestion of proteins takes place in different stages. The initial
phase of protein digestion and absorption occurs in the stomach,
followed by protein digestioninthesmall intestine.Until now, it was
commonly accepted that proteins that are more rapidly absorbed in
the body (also called fast proteins) appear to have a larger effect on
satiety than slow proteins, which coagulate in the stomach and
induce lower levels of amino acids in the bloodstream [21]. In
humans, it has been demonstrated that whey, a fast protein, was
more satiating and induced stronger postprandial hormone release
than casein, a slow protein [22]. It could also be possible that the
‘fast’ proteins are not digested well in the stomach, leaving more
intact protein to enter the duodenum, which in turn might result in
higher satiation. However, no literature is available on the levels of
intact proteins that reach the duodenum.
In the present study, the effects of pea protein on food intake
were studied. This protein contains large amounts of arginine,
asparagine, and glutamine, and is digested by approximately 93%
in the stomach [23]. The study of Diepvens et al showed that pea
protein hydrolysates had a more pronounced effect on PYY
release and feelings of hunger, compared to whey and whole milk
proteins [12]. However, in a recent study from our group we
demonstrated that intact pea proteins were more potent in
stimulating hormone release from enteroendocrine cells, than
protein hydrolysates and specific peptides (accepted in Molecular
Food and Nutrition research, 2010). In another study, we
demonstrated that intact pea and wheat protein stimulated CCK
and GLP-1 release from human duodenal tissue to a greater extent
than egg and codfish protein and negative control [24]. Unlike
other common protein sources such as milk, soy, or wheat
proteins, pea protein has a very low allergenic potential, which
makes this protein more suitable for dietary interventions than
wheat protein.
The present study shows that intact pea protein is more satiating
than its digested products. However, we do not know whether the
subjects compensated the decreased portion size with an increased
Figure 2. Changes in plasma CCK release (pM) after oral and
intraduodenal treatments with pea protein and placebo. CCK
release was increased during the first 10 minutes after oral pea protein
ingestion in both lean (A) and obese (B) subjects. However, after
intraduodenal pea protein administration, CCK levels remained elevated
for 15 minutes, and the levels were higher when compared to oral
protein administration. Values are expressed as mean 6 SEM. *
Significantly different from placebo treatment (p,0.05). # Significantly
different from oral protein treatment (p,0.05).
doi:10.1371/journal.pone.0024878.g002
Figure 3. Changes in plasma GLP-1 release (pM) after oral and
intraduodenal treatments with pea protein and placebo. GLP-1
levels did not change over time after pea protein ingestion in lean
subjects (A), when compared to the placebo treatments. In obese
subjects, GLP-1 levels were significantly increased from 90 minutes after
intraduodenal pea protein administration until the end of the test (B).
Oral pea protein administration did not affect GLP-1 release. Values are
expressed as mean 6 SEM. * Significantly different from placebo
treatment (p,0.05). # Significantly different from oral protein
treatment (p,0.05).
doi:10.1371/journal.pone.0024878.g003
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given is relatively high. Subjects received 250 mg per kg of
bodyweight, which is comparable with a fourth of the daily total
protein intake (approximately 1 gram per kg of body weight per
day [25]). It has previously been demonstrated that this amount of
protein affects satiety [26], and therefore, this amount was also
used in the present study. However, future studies should be
designed to identify the lowest effective dose of this protein. Also,
options for delivering intact proteins to the duodenum will have to
be investigated. There are some studies describing coatings for
enteric delivery, such as pH-triggered (micro)coatings, pressure-
sensitive coatings, or time-release coatings [27,28,29,30,31]. For
duodenal delivery of a large amount of protein, a pH-sensitive
coating seems suitable. It should be noted that, under physiological
circumstances, little intact protein will reach the duodenum.
Administering large amounts of intact protein to the duodenum
might result in decreased feelings of well-being. Here we
demonstrated that these amounts of protein did not affect feelings
of nausea, stomach ache, diarrhoea and other factors of well-
being. As was demonstrated in the past, undigested lipids infused
more distal in the ileum caused similar effects [2]. This pheno-
menon called ‘ileal brake’ could also be active in the present
situation of undigested protein proximal in the small intestinal
tract. The exact mechanisms are still not fully explained as in the
lipid infusion studies as in our intact protein infusions not all gut
hormones respond similar in relation to satiety response. Other
local neurohumoral factors could be involved.
There are indications that obese subjects are less sensitive for
satiety signals compared to lean subjects. In rats it was shown that
the minimal effective dose of satiety hormones was 3–4 times
greater in obese than in lean rats [32,33]. Here we demonstrated
that after the same protein load, CCK levels in obese subjects were
higher when compared to lean subjects, whereas GLP-1 and PYY
levels did not differ between both groups. This would indicate that
there is an impaired balance between protein load sensitivity and
release of CCK in obese subjects. Even though the CCK levels
were higher, both lean and obese subjects decreased food intake
following protein ingestion to the same extent. This suggests that
obese subjects are less sensitive to the satiety signals. Although
there are no indications that age might have an influence on the
present results, we should take into consideration, that even
though not significant, there is a trend that there is a age difference
between lean and obese subjects used in the present study. We
should also take into consideration that perhaps obese subjects are
also more sensitive to external cues that influence the amount of
food eaten [34]. Hence, the laboratory setting may have influen-
ced eating behaviour in the obese subjects to a larger extent than
the lean. However, there were no significant differences between
lean and obese subjects in relation with the appetite ratings. VAS
are often used to measure subjective appetite sensations and the
validity and reproducibility has been shown in several studies
[20,35]. Both groups showed the same changes over time, which
may also explain why both groups consumed the same amount of
food.
Figure 4. Changes in plasma PYY release (pM) after oral and
intraduodenal treatments with pea protein and placebo. Oral
pea protein ingestion did not affect PYY release in lean subjects (A),
whereas intraduodenal pea protein administration significantly in-
creased the release of PYY from 15 minutes after pea protein
administration until the end of the test. In obese subjects (B), PYY
release was significantly increased from 30 minutes until the end of the
test for both protein treatments. Values are expressed as mean 6 SEM.
* Significantly different from placebo treatment (p,0.05). # Signifi-
cantly different from oral protein treatment (p,0.05).
doi:10.1371/journal.pone.0024878.g004
Figure 5. Ad libitum food intake (g) after oral and intraduodenal
treatments with pea protein and placebo. Oral protein ingestion
did not affect food intake. Both lean and obese subjects decreased
food intake after intraduodenal protein administration compared to the
placebo treatment. Moreover, obese subjects decreased their food
intake also when compared to oral protein treatment, whereas this was
not the case for lean subjects. ID: Intraduodenal treatment; O: oral
treatment. Values are expressed as mean 6 SEM. * Significantly
different from intraduodenal placebo treatment (p,0.05). # Signifi-
cantly different from oral protein treatment (p,0.05).
doi:10.1371/journal.pone.0024878.g005
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protein administration in both lean and obese subjects, in contrast
to food intake after oral ingestion of the protein. Although there
were no differences in appetite ratings between both groups, we
observed elevated levels of CCK in obese subjects, and GLP-1 and
PYY were elevated in both groups. This suggests that by preven-
ting gastric pea protein degradation may be an effective dietary
strategy in the prevention and treatment of obesity. However,
more studies will have to be performed to identify the lowest
effective dose of the protein, and whether (micro)encapsulated
proteins show the same effects on food intake. Also, long-term
intervention studies will have to be performed to demonstrate the




Twenty male subjects participated in this study. We included
only male subjects, because with female subjects, the hormonal
fluctuations may influence the satiety hormone levels during this
study. The subjects were recruited by advertisements on boards at
the university and in local newspapers. Selection took place
according to health criteria (no diabetes, no gastrointestinal
diseases, and no medical treatment) and body weight (BW) criteria
(for lean subjects: body mass index (BMI) 18–25 kg/m
2, and for
obese subjects: BMI.30 kg/m
2). Baseline characteristics of the
subjects are presented in table 1. The nature and risks of the
experimental procedure were explained to the subjects, and all
subjects gave their written informed consent. This study was
conducted according to the guidelines laid down in the
Declaration of Helsinki [19]. The Medical Ethical Committee of
the University Hospital Maastricht approved all procedures
involving human subjects.
Nasointestinal catheter
Participants were intubated with a 145 cm nasoduodenal
catheter (Flocare Bengmark, Nutricia, Zoetermeer, The Nether-
lands). This catheter is designed for transnasal feeding directly into
the duodenum or jejunum. The tip of the catheter was lubricated
with lidocaı ¨ne gel to sedate the nostril. The catheter was
introduced into the stomach and the tip was positioned in the
duodenum under radiological guidance and verification.
Experimental design
In this single-blind, randomized controlled crossover design,
each participant participated in four experiments on four
occasions with 1 week between visits. All subjects received a
standardized evening meal (9 g protein, 39,5 g carbohydrates,
16 g fat per meal) on the day prior to the test day to standardize
macronutrient intake. On each occasion, subjects arrived after
fasting overnight. The nasoduodenal catheter and an intravenous
blood sampling catheter were placed during each test day, and a
fasting blood sample was taken. Subjects then completed an
appetite and well-being questionnaire. The test-drink (for composi-
tion see ‘dietary protocol’) was consumed at time 0. During oral
consumption of the test drink, subjects were instructed to consume
the drink within 5 minutes. During intraduodenal infusion of the
drink, the fluid was infused for 30 minutes, at a rate depending on
the volume of the test-drink, which was based on total body weight
of the volunteer. Subsequent blood samples were collected at 0, 5,
10, 15, 30, 45, 60, 75, 90, and 120 min, respectively. An appetite
questionnaire was completed 0, 5, 15, 30, 60, 90, and 120 min,
respectively. A well-being questionnaire was completed 0, 5, 30,
60, 90, and 120 min, respectively. After 120 min, the nasoduo-
denal catheter and the intravenous catheter were removed, and
subjects were offered an ad libitum meal approximately 10 minutes
after the removal of the catheter. Instructions were given to eat
until comfortably satiated.
Dietary protocol
The protein tested was provided as part of a drink (4 ml per kg
of bodyweight), which contained either pea protein (250 mg per kg
of body weight)(Dutch Protein Services, Tiel, The Netherlands) or
only water as placebo. This concentration of protein was chosen,
because it is comparable with the amount of protein that one meal
should contain on average. The drinks were uniformly flavored
with 5 g cream vanilla flavor (Quest International, Naarden, The
Netherlands) per liter beverage to mask the taste of the pea
protein. The drinks were provided in covered flasks so that the
subjects did not know which product they received.
The ad libitum meal consisted of Lasagne Bolognese (671 kJ,
7.5 g protein, 12.3 g carbohydrates, 9.0 g fat per 100 grams).
Food was weighed prior to the meal and after the subjects left the
laboratory. Food intake was assessed by difference.
Questionnaires
The appetite questionnaire was a Visual Analogue Scale
questionnaire (VAS, on a 100 mm scale) with questions about
feelings of hunger, fullness, satiety, thirst, and desire to eat [20].
Opposing extremes of each feeling were described at either end of
a 100-mm horizontal line, and subjects marked the line to indicate
how they felt at that moment.
Well-being was determined using a questionnaire on the
occurrence of complaints (headache, nausea, stomach-ache,
diarrhea, and other symptoms). Symptoms were graded on a 10-
point scale with the grade 1 representing ‘Not present’, to 10
‘Strongly present’. Subjects were asked to mark how they felt at
that moment.
Blood parameters
Blood samples were collected for analysis of Ghrelin, CCK,
GLP-1, and PYY. The blood samples were mixed with EDTA to
prevent clotting. The blood samples for CCK (5 ml) analysis were
mixed with 2000 KIU Aprotinin (VWR International, Amster-
dam, The Netherlands). Samples for GLP-1 (5 ml) were mixed
with 40 ml of a dipeptidyl peptidase IV (DPP-IV) inhibitor (Linco
Research Inc., St Charles, Missouri, USA) to prevent degradation.
Plasma CCK levels were determined by a RIA (Euria-CCK,
Eurodiagnostica AB, Malmo ¨, Sweden). Plasma GLP-1, plasma
total PYY levels, and plasma total Ghrelin levels were also
determined by a RIA (Linco Research Inc., St Charles, Missouri,
USA), all according to the manufacturers instructions.
Table 1. Subject characteristics at baseline.
Lean (n=10) Obese (n=10)
Age (years) 25624 1 66
#
BMI (kg/m
2)2 3 . 0 60.7 33.461.4*
HbA1c (%) 5.060.1 5.060.1
Basal glucose (mmol/L) 4.860.2 4.560.1
All data are mean 6 SEM.
N Difference between lean and obese subjects (p,0.05).
# p-Value=0.054 between lean and obese subject.
doi:10.1371/journal.pone.0024878.t001
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Data are presented as mean 6 standard error of the mean
(SEM), unless otherwise indicated. Statistical analysis was
performed using SPSS 16.0 for Mac OS X software (SPSS Inc,
Chicago, Illinois, USA). Mixed-model ANOVA was used to
determine possible effects between the conditions. Differences in
food intake between conditions and groups were calculated using
the Students t-test. Correction for multiple comparisons was
applied. All statistical tests were performed two-tailed and a p
value of ,0.05 was considered statistically significant.
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